• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

TERT promoter gene mutations in PTCL-NOS

Research Project

Project/Area Number 17K08751
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Human pathology
Research InstitutionKurume University

Principal Investigator

Arakawa Fumiko  久留米大学, 医学部, 助教 (50212618)

Co-Investigator(Kenkyū-buntansha) 大島 孝一  久留米大学, 医学部, 教授 (50203766)
瀬戸 加大  久留米大学, 医学部, 客員教授 (80154665)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Keywordsリンパ腫 / hTERT / hTERT promoter / PTCL-NOS / ATLL / hTERT / TERT promoter / HRM解析
Outline of Final Research Achievements

We investigated the effect of human telomerase reverse transcriptase (hTERT), which is closely related to telomerase activity, on the promoter mutation, protein expression frequency, and pathology in T-cell lymphoma.  Gene analysis of the hTERT promoter was performed in peripheral T-cell lymphoma, nonspecific (PTCL-NOS), and angioimmunoblastic T-cell lymphoma (AITL), which are common in T-cell lymphoma.  Only 2 cases of PTCL-NOS had a gene mutation, and 1 case (known mutation site) also expressed protein, but the remaining 1 case (new site) did not express protein.  The mutation of hTERT promoter does not seem to be directly related to its expression.  A statistical analysis of protein expression revealed that only hTERT-expressing PTCL-NOS had a significantly poor prognosis.

Academic Significance and Societal Importance of the Research Achievements

悪性リンパ腫はリンパ球(主にB 細胞、T細胞由来)が癌化したものである。末梢性T細胞リンパ腫, 非特定 (PTCL-NOS)、血管免疫芽球性 T 細胞リンパ腫 (AITL)は極めて多様性に富む疾患である。hTERTとの関連性は、ほとんど調べられていない。今回、PTCL-NOSで、hTERTタンパクを発現しているT細胞リンパ腫が予後不良であったことは、予後の層別化を行うことが可能となり、今後、そのようなPTCL-NOSに対して何らかの新しい治療法に繋がることが期待される。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (2 results)

All 2020 2019

All Journal Article (2 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 2 results,  Open Access: 2 results)

  • [Journal Article] Genomic Landscape of Young ATLL Patients Identifies Frequent Targetable CD28 Fusions2020

    • Author(s)
      Noriaki Yoshida, Kay Shigemori, Nicholas Donaldson, Christopher Trevisani, Nicolas A Cordero, Kristen E Stevenson, Xia Bu, Fumiko Arakawa, Mai Takeuchi, Koichi Ohshima, Akinori Yoda, Samuel Y Ng , David M Weinstock
    • Journal Title

      Blood

      Volume: 135 Issue: 17 Pages: 1467-1471

    • DOI

      10.1182/blood.2019001815

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)2019

    • Author(s)
      Kawano N, Yoshida N, Kawano S, Arakawa F, Miyoshi H, Yamada K, Nakashima K, Yoshida S, Kuriyama T, Tochigi T, Nakaike T, Shimokawa T, Yamashita K, Marutsuka K, Mashiba K, Kikuchi I, Ohshima K.
    • Journal Title

      Internal Medicine

      Volume: 58 Issue: 15 Pages: 2159-2166

    • DOI

      10.2169/internalmedicine.2513-18

    • NAID

      130007686813

    • ISSN
      0918-2918, 1349-7235
    • Year and Date
      2019-08-01
    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi